No Data
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients With CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for...
Allogene Therapeutics Announces Participation in November Investor Conferences
Earnings Preview: ALLO to Report Financial Results Post-market on November 07
$Allogene Therapeutics(ALLO.US)$ is scheduled to release its financial results post-market on November 07 ET. Earnings PreviewAnalysts estimate $Allogene Therapeutics(ALLO.US)$ to post revenue of USD1
Express News | Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
H.C. Wainwright Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9
Allogene Receives FDA RMAT Designation for Its Metastatic Renal Cell Carcinoma Treatment
No Data
No Data